Table 1.
Comparison of the baseline characteristics between the control group and HD patients with severe anemia
| Controls | HD patients with severe anemia | p value | |
|---|---|---|---|
| Patients | 25 | 16 | |
| Sex (male/female) | 18/7 | 12/4 | 0.881 |
| Age, years | 67.2±9.5 | 64.8±9.8 | 0.435 |
| HD duration, years | 4.6±4.4 | 4.3±6.9 | 0.868 |
| Primary disease | |||
| Diabetic nephropathy | 16 | 7 | 0.120 |
| Nephrosclerosis | 2 | 4 | |
| Chronic glomerulonephritis | 5 | 1 | |
| Others | 2 | 4 | |
| Comorbidities | |||
| Cardiovascular disease | 8 (32.0%) | 8 (50.0%) | 0.410 |
| Cerebrovascular disease | 10 (40.0%) | 3 (18.8%) | 0.279 |
| HD | |||
| Dry weight, kg | 56.8±12.4 | 58.3±8.6 | 0.686 |
| Ultrafiltration, mL/h | 550±201 | 502±237 | 0.484 |
| HD time, h | 3.8±0.4 | 3.7±0.4 | 0.410 |
| Causes of anemia | |||
| Gastrointestinal bleeding | 5 | ||
| Renal anemia | 4 | ||
| Operation-related anemia | 2 | ||
| Inflammation-related anemia | 2 | ||
| Other hemorrhagic disorders | 3 | ||
| Erythropoiesis-stimulating agent, IU/week | 4,560±3,343 | 10,188±6,537 | <0.001 |
| Iron administration (yes/no) | 3/22 | 2/14 | 0.962 |
| Blood transfusion volume, mL | 385±140 |
Values are presented as n, n (%), or mean ± standard deviation. HD, hemodialysis.